Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286793 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
A Phase 1 study of Prostate Cancer, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 13
- Study locations
NCT00286793: Completed Phase 1 study of Prostate Cancer, sponsored by Ascenta Therapeutics.
NCT00286793 is a Phase 1 study of Prostate Cancer that has completed, run by Ascenta Therapeutics. The registered enrollment target is 76 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00286793, a Phase 1 study of Prostate Cancer, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,
Conditions Studied
Interventions
- DRUG AT-101
Study Locations (13)
Tennessee
- - Germantown
- - Memphis
- - Nashville
Arkansas
- - Hot Springs
Florida
- - Fort Meyers
Illinois
- - Chicago
Minnesota
- - Fridley
New Mexico
- - Albuquerque
New York
- - Syracuse
North Carolina
- - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00286793 record still lists
NCT00286793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which AT-101 is the first listed.
NCT00286793 lists 13 locations in 11 states (Tennessee, Arkansas, Florida).
Frequently Asked Questions
What is clinical trial NCT00286793 about?
NCT00286793 is a clinical study titled "Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC". This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,
What is the current status of trial NCT00286793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2006-02. Estimated completion is 2009-11.
What conditions does trial NCT00286793 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00286793?
The interventions under investigation include: AT-101 (DRUG).
Who is sponsoring clinical trial NCT00286793?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00286793 being conducted?
This trial has 13 study locations across Arkansas, Florida, Illinois, Minnesota, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00286793's enrollment target sits among peer trials
76 388th of 735 higher than 345 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia